BioPharma, Pharma

Provention Bio drug for delaying type 1 diabetes hit with FDA delay of its own

Provention Bio needs to show the FDA that the drug substance produced from its contract manufacturer is comparable to the Eli Lilly-made drug substance that was evaluated in clinical trials. A larger study testing the prospective type 1 diabetes therapy teplizumab is ongoing and could provide the information the agency needs.

 

A Provention Bio therapy developed to delay the onset of type 1 diabetes has been turned down by the FDA due to the regulator’s questions about how comparable the drug tested in clinical trials is to the product that the company plans to bring to the market.

There’s still a path forward for the drug, teplizumab, and a clinical trial is already underway that could provide the answers that the FDA needs. But the FDA’s rejection of the antibody will delay indefinitely launch plans for what the Red Bank, New Jersey-based biotech expected would become its first commercialized drug.

Shares of Provention opened Tuesday at $6.40 apiece, down nearly 23% from Friday’s closing stock price.

The FDA is specifically asking questions about teplizumab’s pharmacokinetics (PK)—how it is metabolized and absorbed by the body. Provention Bio acquired the drug from partners Macrogenics and Eli Lilly, and the clinical data supporting Provention’s FDA submission is based on drug substance that was manufactured by Lilly. According to Provention regulatory filings, teplizumab’s concentration in the blood over time is lower for the drug substance made by the biotech’s contract manufacturer.

Provention has done its own modeling to evaluate the differences, and it does not believe that they are significant enough to affect the efficacy or safety of its drug. The FDA is less sure. According to Provention, the FDA’s July 2 complete response letter said that a “bridging” study that compared the drug tested in clinical trials to the planned commercial product failed to show PK comparability. Complete response letters are private correspondence and therefore are not made public. But according to Provention’s summation of the letter, the FDA wants more information.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

“As PK remains the primary endpoint for demonstration of comparability between the two products, you will need to establish PK comparability appropriately between the intended commercial product and the clinical trial product or provide other data that adequately justify why PK comparability is not necessary,” Provention quoted the FDA as saying.

Type 1 diabetes is an autoimmune disorder in which the immune system destroys the pancreas’s beta cells, which in turn affects production of the blood sugar-regulating hormone insulin. The standard of care for type 1 diabetes currently includes insulin therapy and glucose monitoring.

Teplizumab is a monoclonal antibody designed to bind to a cell surface protein called CD3. This protein helps activate T cells and direct various immune responses. Provention said in its regulatory filings that research suggests that binding to CD3 restores immune tolerance and may prevent immune cells from attacking beta cells.

Provention’s submission of teplizumab for FDA review was based on a pivotal study enrolling 76 patients. In results of that that Phase 2 study, a 14-day course of the drug resulted in a median two-year delay of the onset of type 1 diabetes in presymptomatic patients compared to a placebo. Side effects included low levels of a type of white blood cell called a lymphocyte, high levels of liver enzymes, rash, and an immune response called cytokine release syndrome. Results from the study were reported at a 2019 meeting of the American Diabetes Association and were also published in the New England Journal of Medicine.

In May, an independent advisory committee to the FDA narrowly recommended approval of teplizumab, voting 10 to 7 that the drug’s benefits outweigh its risks.

Provention expects to generate additional PK data from an ongoing Phase 3 study in about 300 pediatric and adolescent patients newly diagnosed with type 1 diabetes. The PK data from the study, which are expected later in the third quarter, will be analyzed by an independent third party to maintain the integrity of the placebo-controlled study, the company said. Provention added that it will review the results and then determine whether to submit them to the FDA, along with any other relevant data and analyses.

The FDA’s letter listed some product quality questions, which Provention believes have been addressed in amendments that it has already submitted to its application or can be addressed in the short term. The agency also flagged some deficiencies to a manufacturing facility. Those unspecified problems were not related to teplizumab but will need to be resolved before the drug can be approved, Provention said.

Photo by FDA